Zurcher Kantonalbank (Zurich Cantonalbank) Tricida, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	BUY	$0.14 - $12.49 $21,724 - $1.94 Million	155,178 Added 2108.4%	162,538 $24,000
Q3 2022 Nov 09, 2022	BUY	$8.51 - $13.6 $36,992 - $59,119	4,347 Added 144.27%	7,360 $77,000
Q2 2022 Aug 09, 2022	SELL	$7.31 - $11.85 $1,878 - $3,045	-257 Reduced 7.86%	3,013 $29,000
Q1 2022 Apr 21, 2022	BUY	$7.35 - $10.63 $11,532 - $16,678	1,569 Added 92.24%	3,270 $27,000
Q4 2021 Feb 01, 2022	BUY	$4.19 - $9.56 $7,127 - $16,261	1,701 New	1,701 $16,000
Q2 2021 Jul 30, 2021	SELL	$3.95 - $5.41 $7,793 - $10,673	-1,973 Closed	0 $0
Q4 2019 Jan 21, 2020	BUY	$29.6 - $43.71 $31,020 - $45,808	1,048 Added 113.3%	1,973 $74,000
Q3 2019 Oct 18, 2019	BUY	$29.87 - $42.22 $27,629 - $39,053	925 New	925 $29,000

Others Institutions Holding TCDA

# of Institutions

Shares Held

30K

Call Options Held

124K

Put Options Held

46.5K

View Full List

About Tricida, Inc.

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

More about TCDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account